Normal Estradiol Levels by Age (and Cycle Phase)

What estradiol actually is — and why it deserves its own conversation

Estrogen is not one molecule. It is a family, and estradiol is the dominant, most biologically potent member during the reproductive years. When a clinician orders "an estrogen level" for a woman of reproductive age or in the menopause transition, estradiol is almost always what is being measured, and it is what the reference ranges in this guide describe. Lab reports abbreviate it as E2, which is why patients frequently search for estrogen ranges while holding an estradiol result.

Estradiol is produced primarily by the developing ovarian follicles, which is the single fact that explains most of what follows. Because production is tied to follicular activity, estradiol tracks the ovarian cycle — it climbs as a follicle matures, peaks around ovulation, and behaves differently again in the second half of the cycle. Once the ovarian follicle pool is depleted at menopause, the main production site is gone and levels settle low. This is a physiological transition, not a deficiency disease in the way a vitamin deficiency is.

Its effects are broad. Estradiol acts on the uterine lining, the vaginal and urinary tissues, bone, the cardiovascular system, and the brain, which is why estrogen change produces such a scattered symptom list — hot flashes, sleep disruption, mood shifts, vaginal dryness, urinary symptoms, joint aches. That breadth is also why symptoms so often fail to correlate neatly with a single number. Two women with similar levels can feel completely different, and the same woman can feel different at the same level depending on how fast she got there.

Why there is no single "normal" estradiol level

The premise behind most searches for a normal estradiol level — that there is one target number and yours is either above or below it — does not survive contact with how the hormone actually behaves. Estradiol is a moving value by design. Within a single healthy cycle it travels across a wide span, and reference labs therefore publish separate ranges for different points in that cycle rather than one interval.

This is structurally different from a test like sodium or creatinine, where a single reference interval applies to essentially everyone and a value outside it is a signal. With estradiol, the same absolute number can be reassuring, unremarkable, or unexpected depending on when it was drawn and who was drawn. Interpretation requires context the number itself does not carry.

There is a second layer. Reference ranges describe what is statistically typical in a reference population — they are not treatment targets, and they were never designed to be. Falling inside a range does not mean your symptoms are imaginary, and falling outside one does not automatically mean something is wrong. This gap between "statistically typical" and "right for you" is where most misreading of hormone panels happens.

The published reference ranges by phase and life stage

Mayo Clinic Laboratories publishes adult female estradiol reference values by reproductive phase: approximately 30-100 pg/mL during the follicular phase, 70-300 pg/mL during the luteal phase, and under 15 pg/mL after menopause. Those three intervals do most of the interpretive work on a typical report. Notice how little they overlap at the extremes — a luteal-range value and a postmenopausal value are not close, but a low luteal result and a mid-follicular result sit right on top of each other.

The postmenopausal figure is the one most often misunderstood. A value under 15 pg/mL in a postmenopausal woman is not an abnormal result — it is the expected result. Reading it as a deficiency to be corrected back into the follicular range misrepresents what menopause is. Whether to treat is a symptom-and-risk decision, and the 2022 NAMS hormone therapy position statement frames that decision around symptoms, age, time since menopause, and individual risk rather than around restoring a laboratory number.

One conspicuous absence from that list is a perimenopausal range. There isn't one worth quoting, because the defining feature of the transition is variability rather than a stable displaced level. A perimenopausal woman can produce a value that sits comfortably in the follicular range one week and a much lower one weeks later, with both being genuine. Any source offering you a tidy perimenopausal reference interval is smoothing over the thing that actually characterizes the stage.

Different laboratories also publish slightly different intervals depending on the method and population they validated against. Always read your result against the range printed on your own report rather than one you found online, including this one.

How estradiol moves across a single menstrual cycle

Within one cycle, estradiol follows a recognizable arc. It sits at its lowest in the earliest days, rises as a dominant follicle develops, peaks around the time of ovulation, drops afterward, then rises again through the luteal phase before falling if pregnancy does not occur. Mayo's separate follicular and luteal ranges are the flattened summary of that arc.

The practical consequence is that cycle day is not a nice-to-have detail on the requisition — it is what determines which range applies. A result of 85 pg/mL is squarely typical for the follicular phase but sits at the very bottom of the luteal range. Without knowing the day, a clinician cannot tell whether that number is entirely expected or worth a second look, and neither can you.

This also explains why comparing two of your own results is harder than it looks. Two draws taken at different cycle points are not measuring the same thing, and treating a difference between them as a trend can manufacture a problem that does not exist. Meaningful comparison requires either matched cycle timing or a clinical question that does not depend on timing at all — and when cycles are irregular, matched timing may simply not be achievable.

How estradiol changes across the lifespan

Across a lifetime the pattern is roughly this: cyclical variation within the reproductive years, increasingly erratic variation through the menopause transition, and a low, stable state afterward. The middle stage is the one people find hardest, because it is the only one where unpredictability is the rule rather than the exception. Symptoms during the transition often track the swings as much as any absolute level.

The transition is also not only about estradiol. The SWAN analysis of body composition change across the menopause transition documented that body composition genuinely shifts during this window, which is relevant because so many women are told that changes in weight and body shape at midlife are purely behavioral. There is a real physiological transition underneath, and acknowledging it is not the same as saying nothing can be done about it.

Chronological age is a poor proxy for stage. Two women the same age can be in completely different hormonal states depending on cycle history, surgical history, medical treatments, and individual variation. This is exactly why the STRAW+10 framework stages reproductive aging by menstrual cycle characteristics and clinical features rather than by birthday — and why "levels by age" tables are inherently less useful than "levels by stage" ones.

The measurement problem: immunoassay vs LC-MS/MS

Here is the technical detail most articles skip, and it changes how you should read low results. Estradiol can be measured by immunoassay, which uses antibody binding, or by liquid chromatography-tandem mass spectrometry (LC-MS/MS), which physically separates the molecule and identifies it by mass. Mayo Clinic Laboratories notes that immunoassay methods lack the precision needed at low estradiol concentrations, which is why LC-MS/MS is preferred where accurate low-level measurement matters.

Immunoassays are fast, inexpensive, and widely available. The trouble concentrates at the bottom of the range — which is exactly where postmenopausal results sit, given that Mayo puts the postmenopausal interval under 15 pg/mL. If your result is a low number and a real decision hangs on whether it is 8 or 18, the method used to produce it is not a technicality.

What to do with this: if a low estradiol value is going to drive a clinical decision, it is entirely reasonable to ask which platform ran it. It is also reasonable to be skeptical of small differences between two low results, particularly if they came from different labs or different platforms — that gap may be assay imprecision rather than biology. Consistency of method matters more than the raw value when you are tracking anything over time.

Why a single estradiol test cannot diagnose perimenopause

This is the most common and most consequential misunderstanding about the test. The STRAW+10 staging system, the reference framework for staging reproductive aging, is built primarily on menstrual cycle characteristics — changes in cycle length and regularity — supported by symptoms, with endocrine measures playing a limited supporting role. It is not built on a single estradiol threshold.

The reason is mechanical. Perimenopausal estradiol is variable rather than uniformly low, so any single draw captures one point on a moving line. Draw on a high day and the result looks reproductive-range; draw weeks later and it may look much lower. Neither result is wrong, and neither is diagnostic. A test that can produce opposite-looking answers in the same woman within one month cannot function as a diagnostic gate.

The corollary is liberating: you do not need a lab result to be believed or treated. A clinician can usually stage the transition from your cycle history and symptom pattern in a conversation, which is both more reliable and more accessible than chasing serial hormone panels. If you have been told your symptoms cannot be perimenopause because your estradiol was normal, that conclusion does not follow from how the test behaves.

Where testing does earn its place is in atypical presentations — symptoms unusually early, absent periods, surgical or medically induced menopause, or another condition that needs ruling in or out. Those are specific questions with specific answers, which is a different use case from screening a symptomatic woman with a regular cycle history.

When an estradiol test genuinely helps — and when it misleads

The useful mental filter is to ask, before drawing: what would I do differently depending on the result? If the answer is nothing — because treatment would be symptom-driven either way — the test is unlikely to add much beyond a number to worry about. If a specific decision genuinely branches on the value, the test is doing real work.

Estradiol also rarely travels alone. Depending on the question, it may be drawn alongside FSH, or thyroid function and prolactin when absent periods need explaining, since thyroid disease in particular produces a symptom picture that overlaps heavily with the menopause transition and is far more directly treatable. In suspected PCOS, the 2023 International Evidence-based Guideline sets out a defined diagnostic framework — estradiol alone is not it.

A separate caution: any result drawn while you are on hormonal contraception or hormone therapy reflects that medication as much as your own physiology, and is usually not interpretable as a baseline. If someone is proposing to test you, it is fair to ask what they expect to learn and how the answer changes the plan.

How to read your own estradiol report line by line

Start with the reference range printed on your own report, not one you found online. Labs validate ranges against their own method and population, so yours is the one that applies. Then find the units — estradiol is commonly reported in pg/mL, and comparing a pg/mL value against a range in different units produces alarming nonsense.

Next, locate the context. Which cycle day were you on? Were you on hormonal medication? Which method ran the sample? If any of those are missing, the number is less interpretable than it appears, and that is worth saying out loud at your appointment rather than accepting an interpretation built on a missing variable.

Finally, resist reading a flag as a verdict. An out-of-range flag is generated by comparing your value to a population interval that may not even be the right interval for your situation — a flagged result drawn on the wrong cycle day is a timing artifact, not a finding. Conversely, an in-range result does not invalidate your symptoms. The flag is a prompt for a conversation, not the conclusion of one.

What else is worth testing alongside estradiol

Because estradiol symptoms are nonspecific, a level in isolation frequently answers less than a broader look. Fatigue, low mood, brain fog, hair change, temperature intolerance, and sleep disruption are produced by many things, and several of the alternatives are more directly treatable than the menopause transition. A workup that checks only estrogen and stops risks anchoring on the most emotionally salient explanation rather than the most likely one.

Thyroid function is the standard companion, because thyroid disease mimics the transition closely and responds well to treatment. Prolactin comes into play when periods have stopped. Iron studies are reasonable when heavy bleeding is part of the picture — and heavy or erratic bleeding is common in the transition — because iron deficiency independently produces fatigue and cognitive fog that no amount of hormone adjustment will fix.

Where PCOS is on the differential, the 2023 International Evidence-based Guideline for PCOS lays out the appropriate diagnostic pathway, which is a specific structured assessment rather than a single estrogen value. The general principle: match the panel to the question. Ordering more hormones is not the same as ordering the right ones.

What to do about symptoms regardless of the number

This is the part that matters most, and it is the part usually buried at the bottom of articles about lab ranges. Treatment decisions in the menopause transition are driven by symptoms and individual risk, not by hitting a target estradiol value. The 2022 NAMS hormone therapy position statement frames candidacy around symptoms, age, time since menopause, and personal risk profile — a framework in which your specific number is not the central input.

For genitourinary symptoms specifically — vaginal dryness, discomfort with sex, urinary symptoms — the 2020 NAMS position statement on genitourinary syndrome of menopause describes low-dose vaginal estrogen as acting locally with minimal systemic absorption. That distinction is practically important, because it means a treatment aimed at these symptoms is a different proposition from systemic therapy. ACOG's patient guidance on vaginal dryness covers the non-hormonal options alongside it.

Non-hormonal and behavioral approaches remain part of the picture too — sleep, alcohol and trigger management, exercise, and treating the co-travelers like thyroid disease or iron deficiency. None of this requires a specific lab result to begin. If you are waiting on a number before advocating for your symptoms, you are waiting for permission the test was never designed to give.

Myths and facts about estradiol testing

Myth: there is one normal estradiol level. Fact: reference labs publish different ranges by phase and stage precisely because there is not — roughly 30-100 pg/mL follicular, 70-300 pg/mL luteal, under 15 pg/mL postmenopausal, per Mayo Clinic Laboratories.

Myth: a normal level rules out perimenopause. Fact: STRAW+10 stages reproductive aging clinically, and a single draw in a stage defined by variability cannot exclude it. Myth: low estradiol always means something is wrong. Fact: after menopause, low is the expected physiological state.

Myth: all labs measure estradiol equally well. Fact: Mayo notes immunoassays lack precision at low concentrations, with LC-MS/MS preferred where accurate low-level measurement matters. Myth: you need a level before starting treatment. Fact: candidacy for hormone therapy is a symptom-and-risk conversation under the 2022 NAMS framework, not a lab threshold.

Myth: home hormone test kits give you a different kind of answer. Fact: whatever the collection method, the interpretive problems remain — timing, stage, assay precision at the low end — and a result arriving without clinical context is if anything easier to misread.

Where weight, body composition, and GLP-1 medications fit in

This comes up constantly and deserves a clear answer, because the two topics are adjacent without being the same thing. Body composition genuinely changes across the menopause transition, as documented in the SWAN body composition analysis. Adipose tissue is hormonally active, so weight and estrogen physiology are connected in both directions, and dismissing midlife body change as purely a discipline problem misstates the biology.

What does not follow is that a weight medication is a hormone treatment. Zepbound and Wegovy are FDA-approved for chronic weight management; Mounjaro and Ozempic are FDA-approved for type 2 diabetes, making weight use off-label. In pivotal trials — SURMOUNT-1 ran 72 weeks for tirzepatide and STEP-1 ran 68 weeks for semaglutide — these were studied as obesity treatments, not as interventions on estrogen physiology. Retatrutide remains investigational and is not FDA-approved for any use. None of these are a route to changing an estradiol level.

One label detail is worth knowing if you are in the transition and still fertile or still using contraception: the tirzepatide label carries an oral-contraceptive interaction warning. That is a tirzepatide-specific consideration and does not apply to semaglutide. It is a contraception question rather than an estradiol-level question, but it is exactly the kind of thing that gets missed when hormone care and weight care are handled by different clinicians who are not talking to each other.

A related caution belongs here: the FDA has published concerns about unapproved GLP-1 products marketed for weight loss, including compounded and non-prescription versions. Anything sold as a topical or transdermal GLP-1 is worth particular skepticism — semaglutide is a large peptide at roughly 4114 daltons, and the long-standing 500-dalton rule for skin penetration describes why molecules of that size do not cross intact skin well.

How to decide what to do next

If you are symptomatic and have a broadly typical cycle history, the highest-value next step is usually a structured conversation about symptoms and risk rather than a lab panel. Write down what changed, when it changed, and how your cycles have shifted over the past year — cycle length, regularity, and any skipped months. That history is the raw material STRAW+10 staging actually uses, and it is information only you can supply.

If your presentation is atypical — symptoms well before the usual window, periods that have stopped without explanation, surgical or medically induced menopause — testing moves from optional to useful, and it belongs inside a defined workup rather than as a standalone estradiol draw. Ask which cycle day the sample should come from, and if a low result is going to drive a decision, ask which assay method the lab uses.

Whatever the number says, symptoms are treatable on their own terms. Systemic hormone therapy is a symptom-and-risk decision under the 2022 NAMS framework; local vaginal estrogen is a separate, locally acting option for genitourinary symptoms with minimal systemic absorption. Neither pathway is gated behind achieving a particular estradiol value, and neither requires you to wait for a lab result before raising the conversation.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• Given my symptoms and cycle pattern, would an estradiol level actually change what we do next — or would we treat the same way regardless of the number?
• If we do test, will the lab run an immunoassay or LC-MS/MS, and does that matter for the low levels we would expect in my case?
• Where am I in my cycle right now, and is that the right day to draw this test for the question we are asking?
• What else should we check at the same time — FSH, thyroid, prolactin, ferritin, or anything else that could explain these symptoms?
• Am I on anything — hormonal contraception, hormone therapy, or another medication — that would make an estradiol result uninterpretable?
• If my level comes back 'normal' but I still feel awful, what is the plan? What are we treating and how will we know it is working?
• Am I a candidate for systemic hormone therapy or for local vaginal estrogen, and what in my history would argue for or against each?

Frequently asked questions

What is a normal estradiol level for a woman?

There is no single number. Mayo Clinic Laboratories lists adult female reference ranges of roughly 30-100 pg/mL in the follicular phase, 70-300 pg/mL in the luteal phase, and under 15 pg/mL after menopause. A value is only interpretable once you know where in the cycle or life stage it was drawn. The same 60 pg/mL can be entirely expected mid-follicular and unexpectedly low mid-luteal.

What are normal estradiol levels by age?

Reference labs generally publish estradiol ranges by cycle phase and reproductive stage rather than by chronological age, because two 45-year-olds can be in completely different hormonal states. The practical age story is: reproductive-age cycling women swing within the follicular and luteal ranges each month, perimenopause makes those swings erratic and unpredictable, and after menopause estradiol settles low — Mayo lists postmenopausal values under 15 pg/mL. Age tells you which pattern is likely, not which number you should have.

What is a normal estradiol level in perimenopause?

There isn't a defined perimenopausal reference range, and that is the single most useful thing to know. During the transition estradiol can be low one week and higher than a typical reproductive-age level the next. The STRAW+10 staging system stages reproductive aging primarily by menstrual cycle pattern and symptoms, not by one hormone result — which is why a single estradiol draw cannot confirm or rule out perimenopause.

Can a blood test tell me if I am in perimenopause?

Not on its own. STRAW+10 anchors staging in changes to cycle length and regularity over time, supported by symptoms, with labs playing a limited supporting role. A clinician can usually stage you from your cycle history in a few minutes of conversation more reliably than from a random blood draw. Testing gets more useful when the picture is atypical — very early symptoms, absent periods, surgical or medical menopause, or another condition on the differential.

Why do my estradiol results keep changing between tests?

Three things move at once: the true biological value, the day you drew it, and the assay's own imprecision. Estradiol legitimately swings across a single cycle, and in perimenopause it swings unpredictably. On top of that, Mayo notes immunoassay methods lack precision at the low end, so two draws that look different may reflect measurement noise as much as physiology. Comparing results run on different platforms at different labs compounds the problem.

What is the difference between an immunoassay and LC-MS/MS estradiol test?

Immunoassays detect estradiol using antibody binding and are fast and widely available, but Mayo Clinic Laboratories notes they lack the precision needed at low concentrations. LC-MS/MS physically separates estradiol and measures it by mass, which is why it is preferred where accurate low-level measurement matters. Since Mayo places the postmenopausal range under 15 pg/mL, that low-end precision question applies directly to postmenopausal results. If your number is low and a decision hangs on it, the method matters.

Is low estradiol dangerous?

Low estradiol is the normal, expected state after menopause — Mayo lists postmenopausal ranges under 15 pg/mL — so a low number by itself is not a disease. What matters is context: low estradiol in a woman who should be cycling, or accompanied by absent periods, warrants investigation. And low estradiol with disruptive symptoms is worth treating for the symptoms, regardless of exactly how low the number is.

Does high estradiol mean something is wrong?

Not necessarily. Estradiol rises around ovulation and again in the luteal phase — Mayo's luteal range extends to 300 pg/mL — so higher readings are routine at the right point in the cycle. Fertility treatment, pregnancy, and some hormone therapy also raise levels by design. Persistently high levels outside those explanations are worth discussing, particularly alongside abnormal bleeding.

When during my cycle should I get estradiol tested?

It depends entirely on the question. Because Mayo's follicular and luteal ranges differ substantially, the timing determines which range applies — so ask your clinician which cycle day they want before booking the draw, and record the day you were on when the sample was taken. If your cycles are irregular or absent, there may be no meaningful timing, which is itself a reason the test may not be informative.

Do I need to test estradiol before starting hormone therapy?

Routine estradiol testing is not how candidacy for hormone therapy is decided. The 2022 NAMS hormone therapy position statement frames the decision around symptoms, age, time since menopause, and individual risk profile. Testing may be added when the clinical picture is unclear or when a specific question needs answering, but a number does not substitute for that risk-benefit conversation.

Does local vaginal estrogen change my blood estradiol level?

The 2020 NAMS position statement on genitourinary syndrome of menopause describes low-dose vaginal estrogen as producing minimal systemic absorption — it is designed to act locally on vaginal and urinary tissue. That is precisely why it is often an option for women who cannot or prefer not to use systemic therapy, and why monitoring blood estradiol is not the standard way to manage it.

Can weight, GLP-1 medications, or body composition changes affect estradiol?

Body composition genuinely shifts during the menopause transition — the SWAN analysis of body composition change across the transition documents this. Adipose tissue is hormonally active, so weight change and estrogen physiology interact in both directions. GLP-1 medications like Zepbound and Wegovy are FDA-approved for chronic weight management (Mounjaro and Ozempic are approved for type 2 diabetes, making weight use off-label), not for hormonal treatment, and are not a way to modify estradiol. Note also that the tirzepatide label carries an oral-contraceptive interaction warning, which is a contraception issue rather than an estradiol-level one, and does not apply to semaglutide.

Primary sources

1. Mayo Clinic Laboratories. Estradiol, Serum — Test Catalog (adult female reference ranges; assay method notes).
2. Harlow SD, et al. Executive summary of the Stages of Reproductive Aging Workshop +10 (STRAW+10). J Clin Endocrinol Metab. 2012.
3. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022.
4. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020.
5. ACOG. Experiencing Vaginal Dryness? Here's What You Need to Know (patient FAQ).
6. Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019.
7. 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023.
8. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
9. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021.
10. FDA prescribing information: Zepbound (tirzepatide) — includes oral contraceptive interaction warning.
11. FDA prescribing information: Wegovy (semaglutide 2.4 mg).
12. FDA prescribing information: Mounjaro (tirzepatide), type 2 diabetes.
13. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
14. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000.